Analyst: Lilly’s move creates uncertainty for Novo
It looks like good news for Novo Nordisk that rival Eli Lilly has abandoned its plans to develop a long-acting insulin, but Lilly’s move also creates uncertainty on the insulin market, Sydbank believes.
BY LONNI LYNGE
US-based Eli Lilly, France’s Sanofi, and Novo Nordisk of Denmark are not going to be a fighting trio on the market for long-acting insulins as most observers have thought. Late last week, the American group said it had shelved all further development of its long-acting insulin peglispro – an announcement that could have a huge impact for Novo Nordisk, says Sydbank’s senior analyst Søren Løntoft Hansen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Rebien: Tresiba will not be profitable at first
For abonnenter
US specialist investors underestimate Tresiba
For abonnenter
